[HTML][HTML] Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
H Siebinga, MDM Stokkel, ADR Huitema… - Theranostics, 2022 - ncbi.nlm.nih.gov
Rationale: Physiologically based pharmacokinetic (PBPK) and population pharmacokinetic
(PK) modelling approaches are widely accepted in non-radiopharmaceutical drug …
(PK) modelling approaches are widely accepted in non-radiopharmaceutical drug …
[HTML][HTML] Computer-aided drug design in anti-cancer drug discovery: what have we learnt and what is the way forward??
The escalating prevalence of cancer on a global scale, coupled with the inadequacies of
present-day therapies and the emergence of drug-resistant cancer strains, has necessitated …
present-day therapies and the emergence of drug-resistant cancer strains, has necessitated …
[HTML][HTML] Practical understanding of cancer model identifiability in clinical applications
Mathematical models are a core component in the foundation of cancer theory and have
been developed as clinical tools in precision medicine. Modeling studies for clinical …
been developed as clinical tools in precision medicine. Modeling studies for clinical …
[HTML][HTML] Physiologically based radiopharmacokinetic (PBRPK) modeling to simulate and analyze radiopharmaceutical therapies: studies of non-linearities, multi-bolus …
Background We aimed to develop a publicly shared computational physiologically based
pharmacokinetic (PBPK) model to reliably simulate and analyze radiopharmaceutical …
pharmacokinetic (PBPK) model to reliably simulate and analyze radiopharmaceutical …
[HTML][HTML] Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases
F Liang, Y Zhang, Q Xue, X Zhang - Scientific Reports, 2024 - nature.com
The purpose of this study was to develop and validate a physiologically based
pharmacokinetic (PBPK) model combined with an EGFR occupancy (EO) model for …
pharmacokinetic (PBPK) model combined with an EGFR occupancy (EO) model for …
[HTML][HTML] Non-invasive quantification of 18F-florbetaben with total-body EXPLORER PET
Background Kinetic modeling of 18F-florbetaben provides important quantification of brain
amyloid deposition in research and clinical settings but its use is limited by the requirement …
amyloid deposition in research and clinical settings but its use is limited by the requirement …
[HTML][HTML] Exploring inter-ethnic and inter-patient variability and optimal dosing of osimertinib: a physiologically based pharmacokinetic modeling approach
F Liang, Y Zhang, Q Xue, N Yao - Frontiers in Pharmacology, 2024 - frontiersin.org
Purpose: This study aimed to develop and validate a physiologically based pharmacokinetic
(PBPK) model for osimertinib (OSI) to predict plasma trough concentration (Ctrough) and …
(PBPK) model for osimertinib (OSI) to predict plasma trough concentration (Ctrough) and …
[HTML][HTML] Physiologically Based Pharmacokinetic Modeling of Extracellular Vesicles
Simple Summary Extracellular vesicles (EVs) are cell-derived structures that play a vital role
in intercellular communication and have potential as drug delivery platforms. Physiologically …
in intercellular communication and have potential as drug delivery platforms. Physiologically …
[HTML][HTML] Deleterious association between proton pump inhibitor and protein kinase inhibitor exposure and survival for patients with lung cancer: A nationwide cohort …
C Bordet, M Zureik, Y Zelmat, M Lafaurie… - Cancer Treatment and …, 2024 - Elsevier
Introduction Previous studies have identified an interaction between protein kinase inhibitors
(PKIs) and proton pump inhibitors (PPIs) in patients with lung cancer. This type of interaction …
(PKIs) and proton pump inhibitors (PPIs) in patients with lung cancer. This type of interaction …
Integrated PBPK-EO Modeling of Osimertinib: Predicting Pharmacokinetics, Intracranial EGFR Engagement, and Optimal Dosing Strategies in Clinical Settings
F Liang, Y Zhang, Q Xue, X Zhang - 2024 - researchsquare.com
Objective The purpose of this study was to develop and validate a physiologically based
pharmacokinetic (PBPK) model combined with an EGFR occupancy (EO) model for …
pharmacokinetic (PBPK) model combined with an EGFR occupancy (EO) model for …